A detailed history of Acadian Asset Management LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Acadian Asset Management LLC holds 5,654,878 shares of NKTR stock, worth $6.62 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,654,878
Previous 4,884,594 15.77%
Holding current value
$6.62 Million
Previous $6.06 Million 21.34%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.11 - $1.48 $855,015 - $1.14 Million
770,284 Added 15.77%
5,654,878 $7.35 Million
Q2 2024

Aug 06, 2024

SELL
$0.9 - $1.83 $2.42 Million - $4.91 Million
-2,684,469 Reduced 35.47%
4,884,594 $6.06 Million
Q1 2024

May 10, 2024

SELL
$0.49 - $0.96 $122,373 - $239,751
-249,741 Reduced 3.19%
7,569,063 $7.07 Million
Q4 2023

Feb 13, 2024

BUY
$0.42 - $0.57 $80,814 - $109,677
192,416 Added 2.52%
7,818,804 $4.42 Million
Q3 2023

Nov 13, 2023

BUY
$0.51 - $1.05 $1.65 Million - $3.39 Million
3,230,368 Added 73.48%
7,626,388 $4.54 Million
Q2 2023

Aug 07, 2023

BUY
$0.53 - $1.03 $2 Million - $3.88 Million
3,765,771 Added 597.51%
4,396,020 $2.53 Million
Q1 2023

May 11, 2023

BUY
$0.64 - $3.15 $388,456 - $1.91 Million
606,963 Added 2606.56%
630,249 $442,000
Q4 2022

Feb 14, 2023

BUY
$2.03 - $4.28 $47,270 - $99,664
23,286 New
23,286 $52,000
Q3 2019

Nov 07, 2019

SELL
$16.91 - $36.27 $5.39 Million - $11.6 Million
-319,029 Closed
0 $0
Q2 2019

Aug 08, 2019

BUY
$31.0 - $36.3 $6.34 Million - $7.42 Million
204,394 Added 178.3%
319,029 $11.4 Million
Q1 2019

May 09, 2019

BUY
$31.58 - $46.35 $3.5 Million - $5.14 Million
110,958 Added 3017.62%
114,635 $3.85 Million
Q4 2018

Feb 07, 2019

SELL
$30.43 - $56.65 $210,301 - $391,508
-6,911 Reduced 65.27%
3,677 $121,000
Q3 2018

Oct 30, 2018

BUY
$46.46 - $68.49 $491,918 - $725,172
10,588 New
10,588 $646,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.